Abstract
Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Current Pharmaceutical Design
Title:Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Volume: 23 Issue: 15
Author(s): Tiantian Luo, Ju Wang, Shilei Hao*, Tingwang Guo, Peng Ren, Zhongjun Cheng, Feiyan Gao, Yuhua Gong and Bochu Wang*
Affiliation:
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030,China
Keywords: Brain drug delivery, ischemic stroke, intracerebral hemorrhage, stroke intervention, stroke recovery.
Abstract: Background: Stroke remains the second commonest cause of death and leading cause of adult disability worldwide. Ischemic events account for nearly 85% of all strokes, and hemorrhages account for nearly 15%. Stroke intervention and recovery have been identified as the important factors in the functional outcome of patients with completed stroke. However, the only FDA approved treatment for ischemic strokes is tissue plasminogen activator, and no effective targeted therapy for hemorrhagic stroke exists yet.
Methods: The goal of this work is to review the brain drug delivery systems (BDDS) used for stroke intervention and recovery. Results: Many novel BDDS have been developed for the use of stroke intervention and recovery, including nanoparticles, hydrogels, fibers, liposomes, and so on, which could improve the permeability of blood-brainbarrier (BBB), short half-life, stability in vivo, and reduce adverse effects of drugs. Conclusion: Combined with new drug targets in the treatment of stroke, BDDS will provide more effective therapeutics for stroke intervention and recovery.Export Options
About this article
Cite this article as:
Luo Tiantian, Wang Ju, Hao Shilei*, Guo Tingwang, Ren Peng, Cheng Zhongjun, Gao Feiyan, Gong Yuhua and Wang Bochu*, Brain Drug Delivery Systems for the Stroke Intervention and Recovery, Current Pharmaceutical Design 2017; 23 (15) . https://dx.doi.org/10.2174/1381612822666161025155058
DOI https://dx.doi.org/10.2174/1381612822666161025155058 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dealing with the Substance Abuse Epidemic and Infective Endocarditis:Clinical, Immunologic and Pathogenetic Aspects
Current Vascular Pharmacology Statin Therapy
Current Pharmaceutical Design Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies A Review of Pediatric Mediastinal Masses and Castlemans Disease
Current Pediatric Reviews The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Current Molecular Medicine Docking and Virtual Screening to Identify PKC Agonists: Potentials in Anticancer Therapeutics
Current Computer-Aided Drug Design Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations
Current Pharmaceutical Design Matrix Metalloproteinases
Current Medicinal Chemistry Safety and Efficacy of Intra-arterial Tirofiban Injection During Mechanical Thrombectomy for Large Artery Occlusion
Current Neurovascular Research Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery New Mechanisms and Targets of Subarachnoid Hemorrhage: A Focus on Mitochondria
Current Neuropharmacology Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study
Current Vascular Pharmacology Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Measurement of Cerebral Blood Flow with Near Infrared Spectroscopy and Indocyanine Green Dye Dilution
Current Medical Imaging Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Protecting Endothelium in Cardiovascular Diseases
Current Medicinal Chemistry Haemodynamic Regulation of Gene Expression in Vascular Tissue Engineering
Current Vascular Pharmacology Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Recent Patents Review in Three Dimensional Ultrasound Imaging
Recent Patents on Biomedical Engineering (Discontinued)